# Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study

> **NCT06339138** · — · ACTIVE_NOT_RECRUITING · sponsor: **Mayo Clinic** · enrollment: 589 (actual)

## Conditions studied

- Chromophobe Renal Cell Carcinoma
- Clear Cell Papillary Renal Tumor
- Clear Cell Renal Cell Carcinoma
- Kidney Oncocytoma
- Papillary Renal Cell Carcinoma
- Urothelial Carcinoma

## Interventions

- **OTHER:** Non-Interventional Study

## Key facts

- **NCT ID:** NCT06339138
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-27
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 589 (ACTUAL)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06339138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06339138, "Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06339138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*